Blog

Epilepsy is one of the most common neurologic diseases and affects millions worldwide including over 2 million Americans [1,2]. Fortunately, approximately two-thirds of patients with epilepsy have long-term seizure remission with initial anti-seizure medications (ASMs) [3]. The remaining third suffer most of the morbidity and mortality associated with epilepsy. For these patients, ASMs offer little benefit, leaving them vulnerable to progressive cognitive decline and elevated mortality [4]. Disease-modifying therapies are needed.